THYROID HORMONE MEMBRANE RECEPTOR INHIBITION IN THE TREATMENT WITH REXINOIDS OF CUTANEOUS T CELL LYMPHOMA

STERLE HA; PAULAZO MA; CREMASCHI GA; CERCHIETTI L; DEBERNARDI M; DÍAZ FLAQUÉ MC; CAYROL MF

Buenos Aires

Congreso; Reunión conjunta de Biociencias; 2017

CTCL are exposed to a complex paracrine and endocrine environment that influence their progression from skin to visceral disease. One of the most common treatments for CTCL, the rexinoid bexarotene (Bex), is associated with hypothyroidism being patients candidate for thyroid hormone (TH) replacement therapy. We recently found that TH, mostly through the action on its membrane receptor (mTR, integrin aVb3) is required for the proliferation of T cell lymphomas (TCL), including CTCL. The consequences of TH administration on the activity of Bex in CTCL cells are unknown. Our aim was to study the effect of TH on the anti-lymphoma activity of rexinoids. We first evaluate cell viability and apoptosis induction of human CTCL cells HuT78 and MJ and murine TCL EL4 cells treated with Bex in the presence and absence of physiological levels of TH. As expected, Bex decreased the viability and induce apoptosis on all the cell lines, but in presence of TH both effects decreased by 15- 40% (p